Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.65 |
| ▸ | NOS3 | P29474 | 3/20 | 0.51 |
| ▸ | NOS1 | P29475 | 3/20 | 0.51 |
| ▸ | NOS2 | P35228 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409291 | 0.80 | TMEM97 (0.66) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL6408326 | 0.74 | TMEM97 (0.72) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL6408019 | 0.71 | TMEM97 (0.66) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL12124425 | 0.71 | TMEM97 (0.66) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL12124424 | 0.69 | SIGMAR1 (0.83) | TMEM97NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL21616830 | 0.67 | SIGMAR1 (0.63) | TMEM97SIGMAR1KMT2A | |
| SCHEMBL6408467 | 0.66 | HTR2A (0.58) | SIGMAR1 | |
| SCHEMBL6410846 | 0.66 | EPHA2 (0.48) | SIGMAR1EGFR | |
| SCHEMBL6408957 | 0.65 | HTR2C (0.61) | EGFR | |
| SCHEMBL31757917 | 0.65 | TMEM97 (0.57) | TMEM97NOS3NOS1NOS2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1465630-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057220-A1 | CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY | GLAXO GROUP LIMITED (GB) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154028-A1 | Cyclic urea derivatives with 5-ht2c receptor activity | HTR2C, HTR3C, HTR5A | TMEM97 244/4885NOS3 427/4885NOS1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.